CUTANEOUS MASTOCYTOSIS: TREATMENT

View at publisher Summarise with VIRAT
Authors: Omer Yilmaz Ulutas, Merve Karaca Şahin, Deniz Özçeker
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cutaneous mastocytosis is a rare mast cell disorder that is usually benign and tends to show sponta-neous regression before puberty. As no curative treatment is currently available, management focuses on symptom control and the prevention of mediator-related reactions. Histamine, tryptase, leukot-rienes, and other mediators released from mast cells may cause pruritus, flushing, gastrointestinal complaints, and, less frequently, systemic reactions. Identification and avoidance of triggering factors such as physical irritation, sudden temperature changes, certain medications, infections, and emotional stress are of great importance. First-line pharmacological therapy consists of H1 antihistamines, while H2 antihistamines or proton pump inhibitors may be added in the presence of gastrointestinal symp-toms. In cases with inadequate symptom control, leukotriene receptor antagonists and mast cell stabi-lizers represent alternative therapeutic options. Topical corticosteroids and mast cell stabilizers may be used during acute flares or in patients with extensive cutaneous involvement, whereas systemic corti-costeroids should be administered only for short-term use in severe and refractory cases. Topical cal-cineurin inhibitors and, in selected refractory cases, additional treatment options such as phototherapy or biologic agents, including omalizumab, may be considered. An epinephrine auto-injector should be prescribed for patients at risk of anaphylaxis, and appropriate education should be provided to patients and their families. Treatment strategies in cutaneous mastocytosis should be individualized according to disease subtype, extent of skin involvement, and symptom severity. The management of mast cell diseases is challenging due to their heterogeneous clinical spectrum, and identifying relevant triggers is not always straightforward. The adverse effect profiles of available therapies, including sedation, gastrointestinal side effects, and potential growth or hypothalamic–pituitary–adrenal axis suppression, further limit treatment options.In addition, the withdrawal of certain medications from the market has emerged as a significant challenge, highlighting the need for appropriate alternative therapies and consistent access to specific drug brands and formulations to prevent potential adverse reactions. Be-yond physical symptoms, the disease burden significantly impairs quality of life, as well as school and work performance. Given the relative rarity of these conditions, access to experienced centers may be limited. Therefore, the management and follow-up of mastocytosis should ideally be conducted in experienced centers through multidisciplinary collaboration. Referral to reliable centers and access to evidence-based educational resources are essential components of effective disease management.

Fields of Study & Subjects

Mast cells and histamine Histiocytic Disorders and Treatments Eosinophilic Disorders and Syndromes

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
69–76
Publication date
1 January 2026
Language
EN
Document type
Book chapter